Cyclo Therapeutics shares are trading higher after European Patent Office allows patent for Trappsol Cyclo for Alzheimer's Disease.
Portfolio Pulse from Benzinga Newsdesk
Cyclo Therapeutics shares are trading higher after the European Patent Office allows a patent for Trappsol Cyclo, a treatment for Alzheimer's Disease.
June 12, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cyclo Therapeutics' stock price is expected to rise in the short term due to the European Patent Office granting a patent for Trappsol Cyclo, an Alzheimer's treatment.
The European Patent Office's approval of the patent for Trappsol Cyclo, a treatment for Alzheimer's Disease, is a significant milestone for Cyclo Therapeutics. This news is likely to boost investor confidence in the company and its product, leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100